Initial testing of cisplatin by the pediatric preclinical testing program
Pediatric Blood & Cancer2007Vol. 50(5), pp. 992–1000
Citations Over TimeTop 15% of 2007 papers
Mimi Tajbakhsh, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, John M. Maris, Stephen T. Keir, Jianrong Wu, C. Patrick Reynolds, Malcolm A. Smith, Richard B. Lock
Abstract
Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.
Related Papers
- → Interleucinas na encefalopatia hipóxico-isquêmica(2003)14 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)